Research & News

Weiss Investor Signals Subscription Your Issue
A healthy dose of drug stocks has turned out to be a great investment prescription.
Weiss Ratings Daily
In this segment, Investment Analyst Nilus Mattive discusses strategies like tax-loss harvesting to help you these last few weeks of 2022.
Strategic Options Subscription
In 2022, investors have contended with a messy war in Eastern Europe, worldwide inflation and supply chain bottlenecks. It’s been a tough slog, yet there are better times ahead. The world is...
Weiss Ratings Daily
While this week might not be as exciting as last, we’ve got one very important piece of economic data on Friday.
Strategic Options Subscription Alert
Stocks are kicking off the week with losses and bond yields climbed as a U.S. services gauge rose unexpectedly.
Safe Money Report Subscription Your Issue
Today, I’m talking to Nilus Mattive, associate editor of Safe Money Report.
Safe Money Report Subscription Your Issue
This week, I have the pleasure of sitting down with Kenny Polcari, host of Wealth & Wisdom, who interviews those in the know.
Strategic Options Subscription
Bears started Friday with all guns blazing. The S&P 500 splattered to an early 1.2% loss on a crazy hot November payrolls report. That's when bulls sneaked into the battlefield and nearly...
Weiss Ratings Daily
Investment Analyst Nilus Mattive delves into timely Safe Money strategies, the FTX debacle and an imperfect market priced for perfection.
Weiss Ratings Daily
Despite ongoing interest rate hikes and consumer inflation, strong Black Friday numbers provide hope for a Santa Claus rally this month.